A Phase I Clinical Study to evaluate the safety, pharmacokinetics and anti-tumor activity of NRC-2694-A in patients with advanced Solid Malignancies

Trial Profile

A Phase I Clinical Study to evaluate the safety, pharmacokinetics and anti-tumor activity of NRC-2694-A in patients with advanced Solid Malignancies

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs NRC 2694A (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Natco Pharma
  • Most Recent Events

    • 25 Jan 2014 Planned End Date changed to 13 Jan 2016.
    • 25 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top